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Background: The decline in lung volumes associated with sickle cell disease (SCD) may begin in
childhood. Risk factors for early restrictive lung disease may include SCD severity markers such as
leukocytosis.
Objective: We examined the relationship between early alteration of lung function and extra-pulmo-
nary markers of SCD severity.
Methods: Weanalyzedpulmonary function test results for 184 SCDchildren (meanage12.6 y) enrolled
in a pediatric cohort.
Main results: Total lung capacity (TLC) and vital capacity (VC) were not associated with a history of
acute chest syndrome.LowerTLCvalueswere significantlyassociatedwith three independent factors:
olderage,previousacuteepisodesofanemia<6g/dl,andhigherbaselinewhitebloodcell counts.Only
thebaselineWBCcountandagewere independentrisk factors for lowerVC.Relativerisks tohaveaTLC
or a VC lower than the mediane value in our population were significantly associated to the baseline
leukocytosis (per 109 G/L), after adjustment on age, sex, genotype, baseline Hb, and treatment (RR
(95% CI) Z 1.16 (1.04e1.29) p < 0.009, and 1.17 (1.06e1.29) p < 0.002, respectively). The
obstructive pattern, defined by FEV1/FVC ratio, was not significantly associated to biological
parameters.
Conclusions: Hemolysis and leukocytosis were independent risk factors for an early decline in lung
volumes in this pediatric SCD cohort
ª 2011 Elsevier Ltd. All rights reserved.Pneumologie Pe´diatrique, Hoˆpital des Enfants Malades, 149 rue de Se`vres, 75015 Paris, France.
4 38 17 40.
urt@nck.aphp.fr (C. Delacourt).
1 Elsevier Ltd. All rights reserved.
Lung function in SCD children 789Introduction Among the 159 children with SS/Sb0 SCD, 105 receivedSickle cell disease (SCD) is the most common inherited
disorder in African and Caribbean populations. It is due to
homozygous point mutations in the b-globin gene, leading
to a reduction in the solubility of deoxygenated hemo-
globin.1 The fundamental pathological processes in SCD
include increased red cell fragility, hemolysis, and micro-
vascular obstruction, leading to anemia and ischemia.
Pulmonary complications are responsible for significant
morbidity and mortality, accounting for 21%e85% of deaths
among SCD patients.2e4 Chronic lung disease in adults with
SCD is thought to result from repeated lung damage caused
by pulmonary vaso-occlusion, and is characterized by
abnormal lung function test values, chronic hypoxia,
pulmonary hypertension, diffuse interstitial fibrosis and cor
pulmonale.3,5e9
A restrictive pattern of impairment may also be observed
in SCD children,10 and longitudinal studies have shown that
the decline in lung volumes begins in childhood.11 However,
the pathophysiology of restrictive disease is less well known
in children than in adults. Changes in pulmonary function in
SCD children have not been linked to a specific type of lung
injury or disease.11 However, sickle cell disease is charac-
terized not only by repeated lung injury but also by general
disorders such as hemolysis, endothelial cell dysfunction,
vascular disorders and leukocytosis.7 Biological markers such
as leukocytosis have been linked to disease severity, but their
relation to changes in lung function has not been
studied.2,12,13 A decline in DLCOwith age has also been linked
to markers of vascular disease, such as impaired hepatic and
renal function.14 Here we examined possible relationships
between early alteration of lung function and extra-pulmo-
nary markers of sickle cell disease in a pediatric SCD cohort.
Methods
Patient database
This study was based on the Creteil pediatric sickle cell
anemia (SCA) cohort.15 The cohort comprises children who
were diagnosed at birth by neonatal screening, and chil-
dren who were included later in childhood after moving
from other region or country. All the children were born
between 1978 and 2001.
All clinical events are prospectively collected in a data-
base, together with the results of yearly evaluations per-
formed during crisis-free periods. Vaso-occlusive crises
(VOC) were considered here only if necessitating hospital-
ization. The acute chest syndrome (ACS) was defined as the
occurrence of a new pulmonary infiltrate on chest radiog-
raphy, usually accompanied by chest pain, fever, tachyp-
nea, wheezing or cough.16 The ACS rate was defined as the
number of ACS episodes per year.
In this database, 184 SCD children had undergone lung
function tests (LFT). We retrospectively analyzed the most
recent LFT results for these children with a mean age (SEM)
of 12.6 (0.3) years (range 4.8e20.0). One hundred fifty-nine
patients had sickle cell SS or Sb0 -hemoglobin disease (155
SS and 4 Sb0), and 25 patients had sickle cell SC-hemoglobin
or sickle cell b-thalassemia disease (17 SC and 8 Sb-thal).treatment intensification with hydroxyurea (HU) (n Z 48),
a transfusion program (TP) (n Z 81) or stem cell trans-
plantation (SCT) (nZ 30). Their mean (SEM) age at HU, TP,
and SCT initiation was 7.9 (0.5), 9.2 (0.5), and 10.0 (0.6)
years, respectively.
Lung function testing
Lung function tests (LFTs) were performed in steady-state
clinical conditions, at least two months after the last acute
event. Acceptance criteria for lung function tests were
those recommended by the ATS/ERS task force.17 Patients
who were able to cooperate with testing had measurements
of vital capacity (VC), forced expiratory volume in 1 s
(FEV1), functional residual capacity (FRC) measured by the
helium washout technique, total lung capacity (TLC), and
diffusing capacity for carbon monoxide (DLCO), measured
with the single-breath technique. Reference equations
from Quanjer et al. were used.18 Reference values for TLC,
FEV1, and VC were increased by 12% to account for
ethnicity.19,20 The FEV1/FVC ratio was expressed as Z score
according to recent guidelines.18,21 The lower limit of
normal is defined as the fifth percentile of the distribution
that corresponds to a Z score of 1.64.18,21 Adjustments for
hemoglobin to the measurement of DLCO were performed
as recommended.22 DLCO was further adjusted to the
alveolar volume in order to obtain the transfer coefficient
of the lung for carbon monoxide (KCO).22
A restrictive pattern was defined as a reduction in TLC to
less than 80% of the corrected predicted value.20,23 An
obstructive pattern was defined by a reduction in the FEV1/
FVC Z score to less than 1.64. FEV1 was measured before
and 15 min after bronchodilator challenge (200 mg of sal-
butamol). A positive response was defined as an increase in
FEV1 of at least 12%, with an absolute increase in volume >
200 ml.20,23
Biological values
Biological parameters recorded in the database include
the white blood cell (WBC) count, the neutrophil count,
the hemoglobin (Hb) level, the platelet count, the
hematocrit (Ht), the hemoglobin F (HbF) level, the retic-
ulocyte count and the lactate dehydrogenase (LDH) level.
Baseline values were obtained in children older than 18
months who had had no intensive treatment, no trans-
fusions within the previous 3 months, and no painful crises
within the previous month. Values were also collected at
the time of the pulmonary function tests. In our pop-
ulation, the mean time interval between baseline and
contemporaryvalues was 5.5  0.3 years, and the median
value was 5.3 years. Only 159 patients had available
baseline blood values.
Statistical analysis
Data are reported as means  SEM. The Kolmogor-
oveSmirnov test was applied to test for a normal distri-
bution. Analysis of variance was used to identify relations
between systemic complications (acute chest syndrome,
790 C. Tassel et al.episodes of acute anemia less than 6 g/dl, and abnormal
transcranial Doppler), genetic status and LFT results.
Linear regression was used to compare laboratory values
with LFT results. Variables significant at the 0.05 level
during the univariate analysis were entered in a multivar-
iate regression analysis. Logistic regressions were used to
evaluate relative risks. For all comparisons, p values <0.05
were considered to denote statistically significant
differences.
Results
Characteristics of the patients (Table 1)
A total of 184 children with SCD were analyzed. Eighty-six
percent of the children had the SS or Sb0 genotype. SS/Sb0
patients had significantly more episodes of acute anemia
(<6 g/dl) than SC/Sb patients, and they also had a signifi-
cantly lower body mass index. SS/Sb0 patients also had
lower Hb, and Ht levels, and higher LDH, WBC, neutrophil,
platelet and reticulocyte counts, both at baseline and at
the time of LTF (data not shown).
Lung function test results
Valid VC, FEV1, and TLC values were available for
respectively 182, 179 and 150 patients (Table 2). Twenty
patients (13%) had a restrictive pattern and only 9 patients
(5%) had an obstructive pattern, defined by a FEV1/FVC
ratio lower than 1.6 Z score. Following salbutamol
inhalation, 9 children had improvement in FEV1 of at least
12% (and >200 ml), including 2of the 9 children with lower
Z scores.
Univariate analysis of factors influencing LFT
results
The results of univariate analysis of nominal and contin-
uous variables are shown Tables 2 and 3, respectively.Table 1 Characteristics of the patients.
All patient
Age, y 12.6  0.3
Males, % 56
Height, SD 0.4  0.1
Weight, SD 0.1  0.
BMI 17  0.3
History of ACS, % 57
ACS rate before intensive treatment 0.2  0.0
History of VOC, % 82
Annual VOC rate before intensive treatment 0.9  0.1
History of acute anemia <6 g/dl, % 48
Abnormal transcranial Doppler (>200 cm/s), % 12
The patients were divided into two subgroups according to their geno
ACS Z acute chest syndrome, VOC Z vaso-occlusive crisis, BMI Z bo
a p < 0.05 compared with SS/Sb0 patients.
b p < 0.01 compared with SS/Sb0 patients.
c p < 0.0001 compared with SS/Sb0 patients.Children with the SS/Sb0 genotype had significantly lower
VC and FEV1 values than patients with the SC/Sb geno-
type. The difference in TLC values did not reach signifi-
cance. No difference in FEV1/FVC or Hb-adjusted KCO
values was observed. A history of ACS did not influence the
LFT values. Previous acute episodes of anemia <6 g/dl
were associated with significantly lower TLC and VC values
but not with lower FEV1/FVC values. Children having
received intensive therapies did not differ from children
who had not.
Age strongly influenced LFT results, being negatively
correlated with TLC, VC, FEV1, but not to FEV1/FVC values.
Restrictive abnormalities were found only in children over 9
years of age (mean  SEM: 14.7  0.7). No correlation was
found between age and Hb-adjusted KCO (Table 3). Inter-
estingly, a negative correlation was also found between age
at stem cell transplantation and both TLC (p Z 0.012;
r Z 0.44) and FEV1 (p Z 0.014; r Z 0.387). BMI corre-
lated positively with TLC and VC.
Several biological parameters correlated with LFT
results. TLC values correlated negatively with the following
baseline parameters (Table 3): the WBC count (p < 0.002),
the neutrophil count (p < 0.003), mean corpuscular volume
(MCV) (p < 0.05), the platelet count (p < 0.03), the retic-
ulocyte count (p < 0.03) and LDH (p < 0.02). TLC values
correlated positively with Hb (p Z 0.01) and Ht values
(p Z 0.001). VC values correlated with the same baseline
biological parameters as TLC values (Table 3). FEV1 corre-
lated negatively with the WBC count (p < 0.02), the
neutrophil count (p < 0.007), MCV (p < 0.05), and the
platelet count (p < 0.008), and positively with HbF
(p < 0.05) and Ht (p < 0.02).
The FEV1/FVC ratio did not correlate with any of the
biological values.
Lung volumes measured on the day of lung function
tests correlated with both the WBC and neutrophil
counts (Table 3). Hb-adjusted KCO correlated negatively
with Hb (p Z 0.0003) and Ht (p < 0.0001), and posi-
tively with the reticulocyte count (p < 0.002) and LDH
(p Z 0.0009).s (n Z 184) SS/Sb0 (n Z 159) SC/Sb (n Z 25)
12.7  0.3 12.1  0.6
55 60
0.2  0.1 1.2  0.2b
1 0.2  0.1 0.7  0.3b
17  0.2 19  1a
57 60.0
0.2  0.0 e
85 70,8
0.9  0.1 e
58 0c
13 0
type. Data are means  SEM.
dy mass index.
Table 2 Clinical characteristics and lung function parameters.
TLC (n) VC (n) FEV1 (n) FEV1/FVC (n) Hb-adjusted KCO % (n)
All patients 93.8  1.2 (150) 90.8  1.0 (182) 92.9  1.2 (179) 0.26  0.09 (174) 116.2  2.5 (121)
Genotype
 SS/Sb0 93.0  1.3 (130) 89.5  1.0 (158) 91.9  1.3 (155) 0.28  0.10(150) 116.7  2.9 (103)
 SC/Sb 99.0  3.2 (20) 99.5  3.3 (24)c 99.4  2.6 (24)a 0.11  0.19 (24) 113.7  4.3 (18)
Sex
 Female 93.4  1.7 (65) 92.0  1.7 (80) 93.2  1.9 (80) 0.26  0.14 (77) 105.7  2.6 (49)
 Male 94.1  1.6 (85) 89.9  1.3 (102) 92.6  1.5 (99) 0.25  0.11 (97) 123.4  3.6 (72)c
History of ACS, %
 Yes 94.2  1.7 (85) 92.0  1.4 (103) 94.6  1.5 (101) 0.22  0.11 (99) 118.5  3.6 (74)
 No 93.3  1.6 (65) 89.3  1.5 (79) 90.6  1.8 (78) 0.32  0.15 (75) 112.7  3.1 (47)
ACS rate before
intensive treatment
ns ns ns ns ns
History of VOC, %
 Yes 93.3  1.4 (114) 90.8  1.2 (137) 92.7  1.3 (134) 0.21  0.10 (129) 117.7  2.8 (96)
 No 95.1  2.6 (21) 91.1  2.7 (28) 94.6  3.2 (28) 0.49  0.20 (29) 113.3  7.0 (18)
VOC rate before
intensive treatment
ns ns ns ns Ns
Episodes of acute
anemia <6 g/dl, %
 Yes 89.8  2.2 (46) 89.2  1.5 (60) 92.9  1.7 (58) 0.33  0.15 (59) 117.3  5.2 (40)
 No 100.1  2.1 (51)c 96.7  2.0 (62)b 98.0  2.1 (63) 0.07  0.16 (62) 115.6  3.4 (41)
Abnormal TCD (%)
 Yes 92.9  2.9 (17) 94.0  2.4 (20) 99.0  3.3 (20) 0.71  0.28 (20) 108.3  7.3 (13)
 No 93.8  1.4 (122) 90.6  1.1 (149) 92.4  1.3 (146) 0.20  0.10 (143)a 117.6  2.9 (100)
Atopy
 Yes 94.9  2.0 (59) 91.7  1.8 (73) 93.4  1.8 (73) 0.12  0.16 (72) 115.2  4.6 (49)
 No 94.7  1.8 (65) 92.3  1.5 (79) 95.9  1.7 (76) 0.34  0.11 (76) 119.6  3.6 (56)
HU therapy: ongoing
 Yes 95.4  2.8 (28) 93.5  2.7 (30) 95.4  2.9 (30) 0.02  0.23 (30) 124.3  6.3 (22)
 No 93.9  1.4 (109) 90.9  1.2 (138) 93.6  1.3 (135) 0.32  0.10 (134) 114.9  2.8 (94)
HU therapy: ever
 Yes 92.4  2.4 (42) 91.1  2.0 (48) 93.0  2.3 (46) 0.01  0.16 (47) 118.1  5.5 (37)
 No 94.3  1.5 (94) 90.5  1.3 (119) 92.7  1.5 (118) 0.38  0.11 (114) 115.8  3.0 (75)
TP: ongoing
 Yes 88.4  2.5 (22) 85.5  1.8 (29) 87.6  2.8 (27) 0.53  0.18 (26) 108.8  4.0 (19)
 No 94.5  1.4 (115) 92.0  1.3 (137)a 94.1  1.4 (136) 0.20  0.10 (134) 117.8  3.0 (97)
TP: ever
 Yes 91.6  1.7 (66) 90.1  1.4 (82) 92.7  1.9 (79) 0.45  0.12 (78) 109.9  3.9 (56)
 No 95.8  1.7 (71) 91.7  1.6 (87) 93.4  1.6 (87) 0.14  0.14 (85) 123.0  3.4 (59)a
BMT
 Yes 90.4  2.0 (24) 90.9  1.9 (30) 94.5  2.3 (30) 0.38  0.17 (30) 96.3  4.4 (22)
 No 94.5  1.3 (126) 90.8  1.2 (152) 92.5  1.3 (149) 0.24  0.10 (144) 120.7  2.7 (99)d
Data are means  SEM. TLC, VC and FEV1 are predicted values adjusted for ethnicity. FEV1/FVC expressed as Z score.
HU: hydroxyurea, TP: transfusion program, BMT: bone marrow transplantation (>1 y before lung function tests), TCD: Transcranial
Doppler (abnormal if > 200 cm/s).
a p < 0.05 compared with “Yes”.
b p < 0.01 compared with “Yes”.
c p < 0.001 compared with “Yes”.
d p < 0.0001 compared with “Yes”.
Lung function in SCD children 791When the analysis was restricted to children with SS or
SB0 SCD, most of the results were still significant, and
especially correlations with WBC and neutrophil counts.
When the univariate analysis was restricted to the
159 patients with available baseline values, correlations
between lung volumes and contemporary biological values
were unchanged : current WBC value was significantly
correlated to TLC (p Z 0.007), VC (p Z 0.001), and FEV1(0.002), and current PNN value was correlated to TLC
(p Z 0.005), VC (p Z 0.022), and FEV1 (0.014).
Multivariate analysis of factors influencing LFT
results
All variables significant in univariate analysis were included
as independent variables in stepwise regression analysis.
Table 3 Linear regression analysis between lung function parameters and continuous variables (age, BMI and biological
parameters).
TLC VC FEV1 FEV1/FVC KCO
Age at LFT, y P Z 0.001 p Z 0.042 p Z 0.0008 ns ns
R Z 0.264 r Z 0.151 r Z 0.249
BMI p Z 0.030 p Z 0.003 ns ns ns
r Z 0.181 r Z 0.222
Baseline biological parameters
WBC p Z 0.002 p Z 0.0002 p Z 0.017 Ns ns
r Z 0.282 r Z 0.295 r Z 0.038
Neutrophil count p Z 0.002 p Z 0.002 p Z 0.007 Ns ns
r Z 0.280 r Z 0.263 r Z 0.229
Hb p Z 0.010 p Z 0.014 ns Ns ns
r Z 0.226 r Z 0.197 r Z 0.116
Ht p Z 0.001 p Z 0.001 p Z 0.018 Ns ns
r Z 0.297 r Z 0.269 r Z 0.197
MCV p Z 0.044 p Z 0.012 p Z 0.044 Ns p Z 0.05
r Z 0.184 r Z 0.207 r Z 0.167 r Z 0.192
Platelet count p Z 0.024 p Z 0.0006 p Z 0.008 p Z 0.041 ns
r Z 0. 201 r Z 0. 274 r Z 0. 216 r Z 0.126
Hb F ns ns p Z 0.0426 Ns ns
r Z 0. 172
Reticulocyte count p Z 0.027 p Z 0.035 ns Ns ns
r Z 0. 206 r Z 0. 178
LDH p Z 0.017 p Z 0.006 ns Ns ns
r Z 0. 238 r Z 0. 248
Contemporary biological values
WBC p Z 0.001 p < 0.0001 p Z 0.0003 Ns p Z 0.004
r Z 0.272 r Z 0.315 r Z 0.277 r Z 0.266
Neutrophil count p Z 0.0007 p Z 0.0005 p Z 0.004 Ns ns
r Z 0.285 r Z 0.265 r Z 0.225
Hb ns ns ns Ns p Z 0.0003
r Z 0.323
Ht ns ns ns Ns p < 0.0001
r Z 0.366
MCV ns ns ns Ns ns
Platelet count ns ns ns Ns ns
Hb F p Z 0.0417 ns ns Ns ns
r Z 0.172
Reticulocyte count ns ns ns Ns p Z 0.002
r Z 0.289
LDH ns ns ns Ns p Z 0.0009
r Z 0.329
792 C. Tassel et al.When TLC was the dependent variable, three independent
risk factors were identified, namely age, the baseline WBC
count, and a history of acute anemia. To estimate the
combined effect of these risk factors, we subdivided the
children around the median values of the continuous risk
factors (13 years and 12  109 G/L WBC). The cumulative
effect of previous acute hemolysis and leukocytosis was
clearly more pronounced in older children (Fig. 1). Inter-
estingly, ROC curve analysis also identified 12  109 as the
best baseline WBC cut-off for discriminating between chil-
dren with a restrictive pattern and those with predicted
TLC values of 80% or more (data not shown). When VC was
the dependent variable, only the baseline WBC count and
age were independent risk factors (Fig. 2). Relative risks tohave a TLC or a VC lower than the mediane value in our
population were significantly associated to the baseline
leukocytosis (per 109 G/L), after adjustment on age, sex,
genotype, baseline Hb, and treatment (RR (95% CI) Z 1.16
(1.04e1.29) p < 0.009, and 1.17 (1.06e1.29) p < 0.002,
respectively). Among the factors significantly related to Hb-
adjusted KCO, only the current Ht value was significant in
multivariate analysis (Fig. 3).
Discussion
A restrictive pattern is a known marker of sickle cell lung
disease. In keeping with previous reports, we observed
a significant decline in lung volumes in children with
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Lung function in SCD children 793SCD.10,11,24,25 The frequency of the restrictive pattern in
our population (14%) was very close to previously reported
values.24 Previous pediatric studies showed no convincing
association between lung function measurements and
pulmonary manifestations.25 Similarly, we found no asso-
ciation between previous acute pulmonary manifestations
or vaso-occlusive crisis and the restrictive pattern. Over-
weight was rarely observed in our population and could not
be a significant contributor to the observed restrictive
disease, higher BMI being associated to higher lung
volumes. By contrast, we found a close relationship
between age and lung volumes. These results point to early
onset of pulmonary impairment in childhood, indepen-
dently of previous lung injury. Although this gradual decline80
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Figure 2 VC values stratified according to independent risk
factors, namely the baseline WBC count and age. The chil-
dren were divided into two age groups around the median
of the entire study population (<13 years, and 13 years).
)p < 0.05.in lung volumes with age has previously been reported,10,11
the underlying mechanisms have rarely been explored. Ours
is the first study to identify factors contributing to this
early-onset pulmonary impairment. In particular, we found
that the decline in lung volumes was significantly and
independently linked to two markers of disease severity,
namely hemolysis and leukocytosis. Although our study is
not a longitudinal one, results are based on the prospective
collection of events and treatments in a computerized
database, allowing adjustments for all potential con-
founding factors and limiting bias.
Intravascular hemolysis is a major risk factor for pulmo-
nary complications in SCD,7 but its role in pulmonary
impairment is less clear. In particular, MacLean found no
relationship between lung volumes and contemporary Hb
levels,11 whereas hyperhemolysis was suggested as a signifi-
cant contributor to the development of pulmonary hyper-
tension in another study.26 We found concordant evidence of
a role of hemolysis in pulmonary impairment. Indeed,
a history of acute anemia <6 g/dl was an independent risk
factor for lower TLC values. Furthermore,markers of chronic
hemolysis (lower baseline Hb or Ht, higher baseline reticu-
locyte count or LDH value) also correlated with lower lung
volumes. No such correlations were observed with biological
values collected at the time of lung function tests.
One important result of our study is the identification of
leukocytosis as a key risk factor for a decline in lung
volumes. We found that higher leukocyte counts were an
independent risk factor for lower TLC and VC values.
Univariate analysis found significant correlations between
pulmonary volumes and values of neutrophils or WBC, both
in basal and contemporary situations. However, multivar-
iate analysis highlighted the predominant prognostic
importance of basal values, as commented above for
hemolysis markers. This major prognostic significance of
basal biological values on the severity of subsequent
disease in children has already been reported by our
team,15 as well as by others.8,27,28 In particular, Miller et al.
have demonstrated that baseline levels of hemoglobin and
leukocyte were strongly correlated with subsequent severe
complications of the disease.8 This suggests that basal
values constitute a truer reflection of the phenotype of the
disease, probably because treatments necessitated by the
progressive complications of the disease, including
794 C. Tassel et al.hydroxyurea treatment and transfusion programs, may
modify current biological parameters but not the intrinsic
risk associated with baseline abnormalities. Only one
previous study showed such a correlation, between TLC and
WBC values in HbSS adults.14 The WBC count has recently
emerged as a significant predictor of SCD severity, including
ACS, clinically overt stroke and early death.2,8,29e31 In HbSS
children, elevated WBC count (>11.8  109 G/L) have
previously been linked to an increased risk of silent cere-
bral infarction.31 It is noteworthy that this value is very
close to baseline WBC cut-off (12  109) identifying chil-
dren with a restrictive pattern in our cohort. The reduction
in the white blood cell count associated with hydroxyurea
therapy is linked to the clinical benefit of this treatment,
even in patients who have no increase in hemoglobin F.32
Hydroxyurea therapy did not significantly affect lung
volumes in our population, possibly owing to the lack of
serial measurements.
The mechanisms by which leukocytes may affect lung
volumes are unclear. Leukocytes are able to adhere to
blood vessel walls and to obstruct the lumen. They also
stimulate the vascular endothelium, which in turn enhances
the expression of ligands for adhesion molecules present at
the surface of blood cells. This results in a cascade of
events leading to tissue damage, and an inflammatory
reaction which further favors vessel occlusion.13 Because
previous pulmonary manifestations are not associated with
LFT values, the restrictive pattern probably results from
subclinical obstruction of capillaries and postcapillary
venules, mediated by leukocyte overabundance.33 Even in
the absence of an acute chest syndrome during childhood,
recurrent subclinical microvascular entrapment of eryth-
rocytes and leukocytes probably contributes to occlusion of
the microcirculation, leading to a decline in lung volumes
and in an early restrictive pattern.
Using recent guidelines for expressing FEV1/FVC values,
we found very few children of our pediatric SCD cohort with
an obstructive pattern, much lower to the rate of 35%
reported elsewhere.24,34 This must be due to the more
accurate adjustment to age of recent predicted values for
FEV1/FVC. If we had evaluated the obstructive pattern as
a crude FEV1/FVC ratio lower than 80%, the percentage of
children with airway obstruction would have raised to 20%
(data not shown), closer to previous reports. As for the
restrictive pattern, lower FEV1/FVC values were preferen-
tially observed in older children. We found no association
between FEV1/FVC values and markers of atopy such as IgE
levels or multiallergenic in vitro tests. Airway hyperreac-
tivity has been linked to airway obstruction in SCD.24,34,35
Although we did not perform airway challenge in our pop-
ulation, we did examine the response of airway obstruction
to inhaled bronchodilators and observed significant
reversibility in only 45% of children with lower Z-scores.
This suggests that hyperreactivity is not the main contrib-
utor to airway obstruction.
In our population, Hb-adjusted KCO % values correlated
positively with hemolysis at the time of lung function tests,
higher values being observed in children with lower Hb and
Ht values and higher reticulocyte counts and LDH levels.
Other studies have shown that, compared to controls
matched for age and ethnic origin, SCD children have
a higher mean Hb-corrected KCO.25,36 Several mechanismshave been proposed. In adults with SCD, a positive correla-
tion has been found between the increase in respiratory
resistance, the diffusion capacity, and a history of acute
chest syndrome, suggesting that the main mechanism is an
increase in lung blood volume.34 However, we found no
association between Hb-adjusted KCO % and previous
pulmonary manifestations in our pediatric cohort. An alter-
native explanation is that Hb-adjusted KCO% in patientswith
SCD increases because of the presence of free hemoglobin in
blood, the concentration of which correlates with the
degree of hemolysis.36 Thus, our study is the first to
demonstrate a correlation between Hb-adjusted KCO % and
contemporary hemolysis. We found no relationship between
Hb-adjusted KCO % and age in our population, suggesting
that lung gas transfer in children may be independent of
other lung function abnormalities. Similarly, a previous
study showed no correlation between Hb-adjusted KCO %
and TLC or FEV1/VC.
36 Hb-adjusted KCO % may thus reflect
different underlying mechanisms in adults and children.
In adults with SCD, a negative correlation has been
found between DLCO and age, suggesting that disruption of
alveolar-capillary gas exchanges may contribute to hypox-
emia.14 In addition, no correlation has been found between
DLCO and the severity of anemia. If we assume that
a decreased DLCO value may indicate more severe sickle
vasculopathy in adults,14 and that a major risk factor for
pulmonary hypertension is the severity of hemolytic
anemia,33 it would be interesting to examine whether
elevated KCOc, reflecting hemolytic activity during child-
hood, is an independent risk factor for an early increase in
pulmonary artery pressure.
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